ST. JOSEPH, Mich., Dec. 12 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, today announced that Chang Gung University (CGU), Taiwan has upgraded their MetaCore web portal license to a permanent in house server installation. CGU has also licensed MapEditor, a new customization product for drawing and editing pathways maps using MetaCore's high quality, manually curated back end content database. An extensive group of CGU researchers will be using MetaCore and MapEditor for analysis of gene expression, proteomic and metabolomic data in a broad range of life science fields. They also plan to produce their own pathway maps using MapEditor that will be accessible to the Chang Gung University research community. The agreement was made possible through GeneGo's Taiwanese distributor Tri-I Biotech.
"GeneGo's MetaCore and MapEditor is one of the integrated bioinformatics platforms installed in the Chang Gung Bioinformatics Center for analysis of data generated from research projects of different disciplines. Current and ongoing projects include the identification of biomarkers that can reveal the presence of nasopharyngeal carcinoma (NPC) in a blood test; the Trichomonas vaginalis Systems Biology Project and the Acanthamoeba Expressed Sequence Tag Project. These powerful tools will highly improve our research stretch," said Professor Tang.
"We are pleased that Dr. Tang has extended his MetaCore license and added our latest product, MapEditor," said Julie Bryant, Vice President of Business Development at GeneGo. "Taiwan is an important, fast growing market for us, as its research is well known in different areas of life sciences."
About GeneGo
GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.1, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com.
MetaCore(TM), MetaBase(TM) and MetaDrug(TM) are trademarks of GeneGo, Inc.
GeneGo, Inc.CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,Inc., +1-858-756-7996, julie@genego.com
Web site: http://www.genego.com/
